Lutetium-177-EDTMP / Bone metastasis / Pain palliation / Radionuclide therapy / Therapeutic radiopharmaceuticalSummary. Beta emitting radionuclides have demonstrated excellent properties for radionuclide endotherapy using appropriate carrier molecules. In an effort to search for alternative radionuclides, the preparation of 177 Lu-EDTMP was undertaken, as a palliative agent for bone metastasis. Natural Lu 2 O 3 was irradiated at the RA-3 Nuclear Reactor of the Ezeiza Atomic Center (Argentina). The optimum molar ratio of Lu:EDTMP, the radiochemical purity, the in vivo and in vitro stability and the biological behaviour in Wistar rats and New Zealand rabbits were studied. The results indicate that an excellent alternative therapeutic radiopharmaceutical, with comparable characteristics as its 153 Sm-EDTMP counterpart, was successfully achieved.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.